HF
GALT icon

HRT Financial’s Galectin Therapeutics GALT Stock Holding History

HRT Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Buy
+51,058
New +$155K ﹤0.01% 3280
2025
Q3 		– Sell
-77,200
Closed -$162K – 3132
2025
Q2 		$162K Buy
+77,200
New +$115K ﹤0.01% 2118
2025
Q1 		– Sell
-19,543
Closed -$25K – 2806
2024
Q4 		$25K Buy
+19,543
New +$46.8K ﹤0.01% 2180
2022
Q3 		– Sell
-14,817
Closed -$19K – 3045
2022
Q2 		$19K Buy
+14,817
New +$21.3K ﹤0.01% 2612
2021
Q4 		– Sell
-80,216
Closed -$311K – 3490
2021
Q3 		$311K Sell
80,216
-24,730
-24% -$83.8K ﹤0.01% 2382
2021
Q2 		$335K Buy
+104,946
New +$373K ﹤0.01% 2078
2018
Q4 		– Sell
-15,050
Closed -$90K – 647
2018
Q3 		$90K Buy
+15,050
New +$82.8K 0.01% 366

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

HRT Financial's GALT Position: Q1 2026 in Review

HRT Financial opened a new position in Galectin Therapeutics (GALT) in Q1 2026: 51,058 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #3280 among its holdings. This is a return to the name: HRT Financial previously reported a position in GALT as recently as Q2 2025.

HRT Financial first reported a position in GALT in Q3 2018 and has held it in 7 quarters since. The position peaked at $335K in Q2 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • HRT Financial held 51,058 shares of Galectin Therapeutics worth $142K as of Q1 2026.
  • Galectin Therapeutics was a new HRT Financial position in Q1 2026.
  • Galectin Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3280 holding.
  • HRT Financial first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 7 quarters since.
  • HRT Financial's Galectin Therapeutics position peaked at $335K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.